IL1RL2 and palmoplantar pustulosis: ,24 Furthermore, spesolimab (anti-IL-36 receptor blocker), a monoclonal antibody approved for the treatment of generalized pustular psoriasis, did not reach the phase-2a randomized placebo-controlled trial primary endpoint in PPP either.26